Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.

ABSTRACT:

Background

In the recent phase III trial MPACT the combination of gemcitabine and nab-paclitaxel (Gem/NabP) showed increased overall survival compared to gemcitabine alone in the treatment of advanced pancreatic ductal adenocarcinoma (aPDA). Until now there has been limited information on the clinical benefit and toxicity of the combination regimen in a real world setting. In addition the value for patients with locally advanced rather than metastatic aPDA has been unclear, since the former category of patients was not included in the MPACT trial.

Methods

A multicentre retrospective observational study in the South Eastern Region of Sweden was performed, with the first 75 consecutive patients diagnosed with aPDA (both locally advanced and metastatic disease) who received fir

SUBMITTER: Blomstrand H 

PROVIDER: S-EPMC6325739 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature